Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 30 May 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023.

Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 August 2023.

Since the announcement 22 May of the programme, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	494,000		571,305,404
22 May 2023	80,000	1,177.68	94,214,718
23 May 2023	80,500	1,162.47	93,579,199
24 May 2023	84,000	1,125.85	94,571,234
25 May 2023	83,500	1,129.07	94,277,633
26 May 2023	84,000	1,129.31	94,861,826
Accumulated under the programme	906,000		1,042,810,013

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 11,889,932 B shares of DKK 0.20 as treasury shares, corresponding to 0.5% of the share capital. The total amount of A and B shares in the company is 2,255,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 30 billion during a 12-month period beginning 1 February 2023. As of 26 May 2023, Novo Nordisk has since 1 February 2023 repurchased a total of 9,836,341 B shares at an average share price of DKK 1,070.73 per B share equal to a transaction value of DKK 10,532,047,665.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 57,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

Contact for further information

Media:
Ambre James-Brown [phone] [e-mail]	Natalia Salomao Abrahao (US) [phone] [e-mail]
Investors:
Daniel Muusmann Bohsen [phone] [e-mail]	Jacob Martin Wiborg Rode [phone] [e-mail]
David Heiberg Landsted [phone] [e-mail]	Mark Joseph Root (US) [phone] [e-mail]

Company announcement No 40 /2023

Attachments

• CA230530-Share-repurchase
• 230526 safe harbour transaction details.